BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Neuland accelerates peptide manufacturing expansion to meet rising customer demand

15 September 2026 | News

First commercial peptide manufacturing module now operational, with additional capacity expansion underway

Hyderabad-based Neuland Laboratories is accelerating its peptide manufacturing expansion, as the first of four scheduled modules has commenced operations at its commercial peptide manufacturing site.

Significantly, with foundational infrastructure for the second module already in place, Neuland expects to begin work ahead of the original timeline once customer requirements are finalised — configuration, instrumentation and capacity are currently being defined in close collaboration with the customer whose projects will anchor the expanded capability.

The newly operational module one provides 7000L total reactor capacity, 750L of solid-phase peptide synthesis (SPPS) and 6250L liquid-phase peptide synthesis (LPPS). This enables flexible customer programmes from smallâ??scale to multikilogram quantities for complete peptide APIs – including complex and longâ??chain peptides – as well as commercial scale production of crude peptides.

Additionally, the SPPS and LPPS reactors are housed in different suites enabling parallel operation and are supported by three Dynamic Axial Compression (DAC) columns [one 45 cm and two 60 cm] and two lyophilisers with 100 L and 200 L capacities.

Following the $30 million investment in module one, Neuland is aligning further investment for subsequent modules with new customer requirements. Module two is planned to provide an overall reactor capacity of up to 18,000 L, comprising three 5,000 L LPPS reactors, as well as either a 1,000 L or 2,000 L SPPS reactor, and smaller reactors of up to the 1,000 L scale. This flexible configuration will allow Neuland to support a broad range of peptide programmes and production scales.

The range of partner indications is also broadening beyond obesity and metabolic disease, with oncology emerging as a particularly active area of early-stage development. As peptide pipelines expand, a growing number of biotech companies are struggling to access capable outsourced development and commercial manufacturing capacity.

Module one is supported by a team of nearly 212 peptide experts and this latest news follows on from an impressive few years for the CDMO. Revenues rose by a massive 116.3% in its most recent quarterly results, driven chiefly by increased commercial contracts, as well as a growing number of clinical projects.